IL6 and gastrointestinal disease: Recent studies using rat models of gastrointestinal disease have found that taVNS upregulates intestinal ACh and α7nAChR expression, while simultaneously reducing the levels of inflammatory cytokines such as TNF-α, IL-1β, and IL-6 [53].